Amorfix produces high-affinity antibodies to DSEs

Amorfix Life Sciences (TSX:AMF), together with its partner, has produced high-affinity antibodies to prion protein disease-specific epitopes (DSEs), which bind preferentially to several cancer primary cells and tumour cell lines, but not normal cells. “This represents a significant milestone for our cancer therapeutic antibody program,” CEO Dr. Robert Gundel said in a statement. “The generation [...]

Amorfix and Epitomics to develop monoclonal antibodies

Amorfix Life Sciences (TSX:AMF) and Epitomics of California and China have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes on misfolded proteins with its ProMIS platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies. [...]